<DOC>
	<DOCNO>NCT00566397</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety PF 04494700 participant mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Mini Mental State Exam ( MMSE ) score 1426 ( inclusive ) screening . Participants must receive acetylcholinesterase inhibitor stable dose least 4 month prior randomization Current evidence history neurological , psychiatric illness could contribute nonAlzheimer 's dementia . Known history familial AD evidence early onset AD known possibly associate genetic mutation . Evidence history diabetes mellitus Type 1 Type 2 . History symptom autoimmune disorder .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>RI RI Study Rage Inhibitors</keyword>
</DOC>